Skip to content
Screener

Aclaris Therapeutics ACRS Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$1.6MBeat by $246.1K
EPS-$0.15Beat by $0.01
Revenue estimate$1.4M
EPS estimate-$0.16
“The first half of 2026 was a period of strong execution across the organization, positioning Aclaris for an exciting second half of the year with numerous expected key catalysts. We expect to provide three clinical data readouts, including placebo-controlled top line results from our two Phase 1b POC trials of our anti-TSLP/IL-4Rα bispecific antibody ATI-052 in both asthma and atopic dermatitis and the Phase 2 AD trial of our anti-TSLP monoclonal antibody bosakitug. Other key catalysts include initiation of a Phase 2b clinical program with ATI-052 and a Phase 2b trial in lichen planus with modzatinib. Finally, our data presented recently at the FASEB Immunoreceptors and Immunotherapy conference support the best-in-class potential of our investigational ITK inhibitor ATI-9494, for which we expect to file an IND late this year.”
Dr. Neal Walker

Next report

Nov 5, 2026 (in a month)
Revenue estimate$1.3M
EPS estimate-$0.16

Financials

Q2 2026

Income statement

See full
Revenue$1.6M-8.3%
Gross profit$1.4M+11.8%
Operating income-$24.2M-31.7%
Net income-$21.5M-39.4%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$19.2M-24.5%
Total debt$1.9M-21.8%
Total equity$124.6M-5.4%
Total assets$179.7M-5.0%

Cash flow

See full
Operating cash flow-$19.8M-98.6%
CapEx$58.0K+176%
Free cash flow-$19.9M-98.8%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$649.15M+226%
Enterprise value$631.83M+258%
P/S79×+66.3×

Profitability

See full
Gross margin79.5%-6.3pp
Operating margin-1,050.2%+266pp
Net margin-921.5%+161pp
FCF margin-756.5%—

Returns & leverage

See full
Return on equity-59.1%-17.4pp
Debt / equity0×0.0×
Current ratio3.5×-0.4×

Segments

By product

See full
Dermatology Therapeutics$1.3M—
Contract Research$356.0K—

By segment

See full
Single Reportable$1.6M—

FAQ

When did Aclaris Therapeutics report Q2 2026 earnings?
Aclaris Therapeutics (ACRS) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Aclaris Therapeutics's Q2 2026 revenue and EPS?
Aclaris Therapeutics reported revenue of $1.6M and eps of $-0.15 for Q2 2026.
Did Aclaris Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $1.4M by $246.1K. EPS beat the consensus estimate of $-0.16 by $0.01.
How did Aclaris Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 8.3% from $1.8M a year earlier and eps declined 15.4% from $-0.13.
Where can I find Aclaris Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-091629) and the 10-Q periodic report (0001104659-26-092065) directly on SEC EDGAR. The filing index links above go to sec.gov.